Featuring application examples and case studies, this Guide from Waters demonstrates how a holistic DMPK approach can transform complex data into actionable insights, helping researchers make more informed decisions throughout drug discovery and development.    Learn more here >>> hubs.ly/Q04ySGkc0

Just caught up with Troy Voelker from Aliri about their 1-year update from the Oligonucleotide Ring Trial, which evaluates multiple assay platforms developed for the same analyte (in this case, an ASO, siRNA and PMO), including hybrid LC-MS and ligand-binding assays. The update includes an evaluation of the same samples by PCR, as well as a comparison of two non-analyte-specific sample preparation techniques (solid phase extraction and protein precipitation) to the data obtained by hybrid LC-MS. We also discuss which topics Troy thinks will gain traction in 2027 and how Aliri are adapting to those trends! #Aliri #LCMS #PharmSci360 #LBA #LCMS #PCR

Final chance to enter the prize draw at #PharmSci360 to win your own mini LEGO laboratory set! Come and visit Bioanalysis Zone at booth 829, or fill in the short form here: hubs.ly/Q04CBWHB0

How can complementary proteomic technologies be used across discovery and bioanalytical workflows? Learn more >>> hubs.ly/Q04C7xMt0

Interested in the Activin E biomarker? Learn more about a hybrid LC–MS/MS assay that helps quantify the Activin E biomarker in human serum in this Case Study from @Resolian_   Download here >>>  hubs.ly/Q04zpZSf0

Reminder to visit booth 829 at #PharmSci360 for your chance to win a mini LEGO laboratory set and bag a few freebies 🎁 Here are some of our favorite stickers on offer 👀 Come and choose yours!

Day 2 of AAPS #PharmSci360! Here are the sessions on our agenda today:  ➡️ [9:00-9:15] Immunogenicity Expectations: Myth-Busting and Evidence Review, with Lauren Stevenson  ➡️ [9:15-9:30] FDA Perspective on Immunogenicity Risk Assessment and Tiered Assays, with Sarah Kirshner  ➡️ [10:30-11:00] Reagent Preparation and PK Method Development for Immuno-PCR Bioanalysis, with Yang Chao  ➡️ [13:30-14:30] Keynote: Converging Platforms and Expanding Biological Insight, with Karan Agrawal and Troy Voelker  ➡️ [15:10-15:30] PBPK Modeling of GLP-1 Agonist DDIs: An Industry Approach

What are the key regulatory checkpoints for ADC LBA validation?  We've collated the core information you need from ICH M10 (2022) and the AAPS ADC Working Group White Paper (July 2026).  Download the #infographic for free here >>> hubs.ly/Q04z-PJd0

What's the key to successful mRNA-LNP development? Learn integrated DMPK, bioanalytical and toxicology approaches that characterize disposition and support IND decisions. Join us: hubs.ly/Q04Bg3n60

Get to know one of the Editors behind Bioanalysis Zone 🎤 Sneak peak of our upcoming partnership with the hosts of the BioTalk Unzipped podcast! A bit of a different one this time...our Editor Emma will be interviewed behind the camera! We love a good uno reverse card 🔄 Host Gregory Austin asks Emma about her background and journey working at Bioanalysis Zone, as well as upcoming industry trends she's excited about. We'll be publishing the interview on Bioanalysis Zone and on BioTalk Unzipped, so stay tuned... 👀

Millions of women worldwide face barriers to routine cervical cancer screening, but a new partnership between Waters Corporation and Quest Diagnostics aims to make testing more accessible through at-home sample collection. Find out more about the test and how to access it here: hubs.ly/Q04BWmfx0

Don’t miss our next webinar with BioAgilytix, ‘Streamlined preclinical bioanalytical strategies: accelerate time to IND.’ Register now >>> hubs.ly/Q04zwwVC0

There’s just ONE WEEK LEFT to complete our survey on biomarkers in bioanalysis.   Enter our #PrizeDraw to win a USD $100 voucher. The survey ends October 29, 2026, so don’t miss out! >>> hubs.ly/Q04zg4LX0

An empowering and fascinating opening plenary at #PharmSci360 from Julie Gerberding, President and Chief Executive Officer of the Foundation for the National Institutes of Health! A quick summary for those who missed it: ⭐ AI's role in drug discovery is still early, we don't yet know if it will outperform conventional discovery. ⭐ We have to modernize preclinical assessment, and that's where the FDA are backing new approach methodologies. ⭐ It's important to focus on end-to-end patient participation in clinical trials, not as an after thought. New awards are recognizing this value, such as the inaugural 2026 Prix Galien USA Patient First Award, which will be presented soon! ⭐ There is an increasing emphasis on defining both valid and qualified (context-of-use) biomarkers. Looking ahead, biomedical innovation will involve integrating novel alternative methods, AI, adaptive trial advancements, and other emerging techniques to enhance both the efficiency and safety of translational medicine. What were your thoughts on the talk? Comment below 👇

❔What's on your #PharmSci360 agenda❔ Here are a few of the talks that we're looking forward to: 🔬 Immunogenicity risk assessment of novel modalities using NAMs, with Sharon Vijayanand 🔬 Rapid Fire: Pushing the boundaries of hybrid LC–MS bioanalysis, with Robert MacNeill (special shoutout!) 🔬 Hot topic: Immunogenicity expectations: are they fact or fear? with Susan Kirshner and Paramita Mookherjee 🔬 Bioanalytical strategies for antibody-oligonucleotide conjugates (AOCs) with Padmanabhan Eangoor 🔬 Symposium: Biomarker-to-decision: biomarker contexts of use and fit-for-purpose strategies with Amanda Hays as Moderator Which will you be attending?

We can’t wait to see many of you tomorrow at #PharmSci360 2026! We’ll be at booth 829 bright and early so stop by the booth to have a chat! 🌄 @aapscomms (hubs.ly/Q04BSkVz0)

It's almost time...🕑 We’re excited to be an official Media Partner of #PharmSci360! Keep your eyes peeled for exclusive interviews with conference presenters, plus our conference report highlighting some of the exciting talks taking place throughout the week!

Check out our 2-minute video on ‘Addressing ligand binding assay challenges in ADC analysis’ as part of our latest In the Zone with @GyrosProteinTec!  Watch now >>> hubs.ly/Q04z-PPg0

Successful #biomarker programs start with alignment 🤝   Whether you're an experienced Sponsor or new to biomarker assay development, collaboration between CROs and Sponsors is critical. This Spotlight shares both perspectives, revealing how clear communication, shared understanding of context of use, and integrated PK-biomarker strategies lead to faster timelines and better outcomes.  Find all of our resources here, in partnership with @Resolian_ >>> hubs.ly/Q04zg2fM0

How do you de-risk mRNA-LNP therapeutics? Our 4 November webinar covers integrated strategies for biodistribution, bioanalysis and safety assessment to help you make confident IND-enabling decisions. Register >>> hubs.ly/Q04BghNp0